Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70447 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2026. Written by Mathias Jachs and 17 co-authors. Institution: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Major MEDLINE topics: Indocyanine Green, Acute-On-Chronic Liver Failure, Liver Cirrhosis, Hypertension, Portal. Cited 4 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Fonds Zukunft Österreich.
Abstract (original language)
Background
Indocyanine green (ICG) clearance, determined by venous sampling, has shown promising results in the diagnosis of clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD) and prognostication in decompensated ACLD (decompensated cirrhosis). Data on ICG clearance measurement by pulse dye densitometry (PDD) via finger clip are comparatively scarce.
Aims
To evaluate the diagnostic (CSPH) and prognostic utility of ICG clearance throughout ACLD stages.
Methods
ACLD (liver stiffness ≥ 10 kPa) patients undergoing same‐day hepatic venous pressure gradient (HVPG) measurement and ICG clearance assessment via PDD in 2017–2022 were recruited from the prospective Vienna Cirrhosis Study (VICIS, NCT03267615).
Results
Two hundred and sixty‐one ACLD patients (cACLD: n = 115, decompensated cirrhosis: n = 146) were included. Among cACLD patients (CSPH: 62.4%), ICG retention 15 min (ICG‐R15) correlated moderately with HVPG (Spearman's rho:0.458; p < 0.001) and yielded a suboptimal diagnostic accuracy for CSPH (AUROC: 0.687 [95% CI: 0.585–0.789]). ICG‐R15 showed a strong correlation with the model for end‐stage liver disease score (rho: 0.701; p < 0.001) and correlated with biomarkers of endothelial dysfunction (von Willebrand factor), systemic inflammation (C‐reactive protein, procalcitonin, interleukin 6) and extracellular matrix remodelling (enhanced liver fibrosis test). In decompensated cirrhosis, ICG‐R15 additionally correlated with mean arterial pressure, serum sodium and renin levels. ICG‐R15 predicted decompensation (subdistribution hazard ratio [SHR]: 1.042 [95% CI: 1.008–1.077] per %; p = 0.014) in cACLD and independently predicted ACLF/liver‐related mortality in decompensated cirrhosis (adjusted SHR: 1.062 [95% CI: 1.025–1.100] per %; p < 0.001).
Conclusions
ICG‐R15 by PDD correlates with portal hypertension and systemic inflammation/circulatory dysfunction as key disease‐driving mechanisms in ACLD. While showing insufficient discrimination for CSPH, ICG‐R15 independently predicted ACLF/liver‐related mortality in decompensated cirrhosis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
- Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
- Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria.
- Gastroenterology Department, Unidade Local de Saúde de Braga, Braga, Portugal.
- Christian Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria.
- Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria.
ORCID profiles: Mathias Jachs, Tânia Carvalho, Benedikt Simbrunner, Georg Semmler, Lukas Hartl, Lorenz Balcar, Benedikt Silvester Hofer, Paul Thöne, Nina Dominik, Georg Kramer, Christian Sebesta, David Bauer, Matthias Pinter, Thomas Reiberger, Mattias Mandorfer
Funding
- Fonds Zukunft Österreich
Cite
APA
Jachs, M., Carvalho, T., Simbrunner, B., Semmler, G., Hartl, L., Balcar, L., Hofer, B. S., Thöne, P., Dominik, N., Kramer, G., Sebesta, C., Schwarz, M., Bauer, D., Stättermayer, A. F., Pinter, M., Trauner, M., Reiberger, T., & Mandorfer, M. (2026). Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70447
Vancouver
Jachs M, Carvalho T, Simbrunner B, Semmler G, Hartl L, Balcar L, et al. Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70447
BibTeX
@article{Jachs2026,
author = {Jachs, Mathias and Carvalho, Tânia and Simbrunner, Benedikt and Semmler, Georg and Hartl, Lukas and Balcar, Lorenz and Hofer, Benedikt Silvester and Thöne, Paul and Dominik, Nina and Kramer, Georg and Sebesta, Christian and Schwarz, Michael and Bauer, David and Stättermayer, Albert F and Pinter, Matthias and Trauner, Michael and Reiberger, Thomas and Mandorfer, Mattias},
title = {Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70447}
}
EUVIMED